Use of anti-EGFR agents among elderly patients with metastatic colorectal cancer (mCRC).

被引：0
|
作者：
D'Silva, Ashley James
Dotan, Efrat
Kloth, Dwight D.
Beck, Andrew
Cohen, Steven J.
Denlinger, Crystal Shereen
机构：
[1] Temple Univ Hosp & Med Sch, Philadelphia, PA 19140 USA
[2] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.657
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
657
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Liquid biopsy driven anti-EGFR rechallenge in metastatic colorectal cancer
    Puzzoni, M.
    Giampieri, R.
    Mariani, S.
    Ziranu, P.
    Pusceddu, V.
    Donisi, C.
    Persano, M.
    Pinna, G.
    Cimbro, E.
    Parrino, A.
    Pretta, A.
    Lai, E.
    Liscia, N.
    Lupi, A.
    Giglio, E.
    Palomba, G.
    Casula, M.
    Pisano, M.
    Palmieri, G.
    Scartozzi, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S543 - S544
  • [32] Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
    Cristiana Lo Nigro
    Vincenzo Ricci
    Daniela Vivenza
    Cristina Granetto
    Teresa Fabozzi
    Emanuela Miraglio
    Marco C Merlano
    World Journal of Gastroenterology, 2016, (30) : 6944 - 6954
  • [33] Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
    Di Fiore, F.
    Sesbouee, R.
    Michel, P.
    Sabourin, J. C.
    Frebourg, T.
    BRITISH JOURNAL OF CANCER, 2010, 103 (12) : 1765 - 1772
  • [34] Drivers of secondary resistance to anti-EGFR therapy in metastatic colorectal cancer
    Noseir, Soha Hussein
    Hahn, Stephan
    Maghnouj, Abdelouahid
    Ladigan, Swetlana
    CANCER RESEARCH, 2020, 80 (16)
  • [35] MicroRNAs and response to anti-EGFR therapy in metastatic colorectal cancer.
    Blanco-Calvo, Moises
    Haz-Conde, Mar
    Rodriguez-Rigueiro, Teresa
    Figueroa, Angelica
    Reboredo, Margarita
    Medina Villaamil, Vanessa
    Lorenzo-Patino, Maria J.
    Arnal, Francisco
    Anton-Aparicio, Luis
    Alonso-Jaudenes Curbera, Guillermo
    Valladares-Ayerbes, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
    Lo Nigro, Cristiana
    Ricci, Vincenzo
    Vivenza, Daniela
    Granetto, Cristina
    Fabozzi, Teresa
    Miraglio, Emanuela
    Merlano, Marco C.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (30) : 6944 - 6954
  • [37] Drivers of Secondary Resistance to Anti-Egfr Therapy in Metastatic Colorectal Cancer
    Noseir, Soha
    Hahn, Stephan
    Maghnouj, Abdelonahid
    Ladigan, Swetlana
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 219 - 219
  • [38] Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer
    Rolfo, Christian
    Bronte, Giuseppe
    Passiglia, Francesco
    Papadimitriou, Konstantinos
    Russo, Antonio
    Peeters, Marc
    CURRENT COLORECTAL CANCER REPORTS, 2013, 9 (03) : 250 - 260
  • [39] First-line anti-EGFR or anti-VEGF therapy in metastatic colorectal cancer (mCRC) by tumour sidedness: Results from the South Australian mCRC registry
    Krishnan, Tharani
    Piantadosi, Cynthia
    Karapetis, Christos
    Townsend, Amanda
    Roy, Amitesh
    Geerinckx, Barbara
    Maddern, Guy
    Roder, David
    Padbury, Rob
    Price, Timothy
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 40 - 41
  • [40] Comprehensive analysis of egfr and its downstream pathways deregulation identifies the vast majority of metastatic colorectal cancer (mCRC) patients resistant to anti-egfr monoclonal antibodies (MoAbs)
    Frattini, M.
    Molinari, F.
    De Dosso, S.
    Martin, V
    Crippa, S.
    Saletti, P.
    Mazzucchelli, L.
    VIRCHOWS ARCHIV, 2009, 455 : 46 - 46
12345